This collaboration combines real world clinical EMR data from a large footprint of cancer centers with research grade multi-omics data collected at key treatment timepoints. These data and linked biobanked samples support discovery of novel biomarkers that will inform treatment decision-making and improve patient outcomes.
The ONCare Alliance, representing 32 independent oncology practices, has partnered with Ovation.io, Inc., a human omics data company, to generate novel biomarker profiles and a biorepository for precision medicine. As multi-omics becomes the new frontier in oncology, collecting blood samples at specific timepoints in the patient journey builds cohorts for standard clinical research. This model bridges clinical trial-type biospecimen collections with real-world clinical data. Serial collections support newer analytes like RNA and proteomics to understand cancer biology. ONCare manages patient enrollment and site management, while Ovation generates and biobanks the -omics data. Clinical data linked to each specimen includes demographics, disease severity measures, treatments administered, and outcomes.
Ovation will integrate -omics data and banked biospecimens with expertly curated de-identified clinical data from electronic medical records (EMR). Clinical trial-level data elements are abstracted from EMR sources to characterize key endpoints. This ensures each patient in the resulting omics data asset has a complete clinical profile, including elements beyond real-world data marketplace. Aggregated data will be shared with the cancer consortium for research.
Two cohorts of breast cancer patients and one cohort of non-small cell lung cancer patients are being collected, with expansion planned. Twelve cancer centers are active, with more to come.
Also Read: Deciphex Raises $32.3M Series C to Tackle Pathology Shortage
“We’re thrilled to partner with ONCare to create a program focused on generating impactful -omics data that will accelerate biomarker discovery for high-need patient populations,” said Ed Stepanski, PhD, General Manager of Data at Ovation. “By combining our strengths, we can generate novel longitudinal datasets at scale that will power significant advancements in drug discovery.”
“Collaborating with Ovation supports our efforts to accelerate personalized diagnostic and therapeutic interventions for cancer patients,” said Sibel Blau, MD, CEO of ONCare Alliance.
As precision medicine evolves, multi-omics is the new frontier in oncology, as most real-world clinico-genomic datasets are derived from somatic tumor tissue. The emerging data asset will be distinguished by its analytical depth and chronology of multiple, sequential sampling, offering researchers a unique opportunity to explore temporal dynamics leading to therapeutic breakthroughs.
Source: Businesswire
